HER2 Support Group Forums

Just received the following from BCT (https://www.breastcancertrials.org/bct_nation/home.seam):

Dear BCT Community:

Scientists, clinicians, and patients from all over the world gathered last week for the 34th annual San Antonio Breast Cancer Symposium. Among the highlights of this year's conference:

Zoledronic Acid (Zometa) shows long-term benefit in survivorship for pre-menopausal women
Dual HER2 blockade significantly extends progression-free survival (Cleopatra Trial)
Exemestane Plus Everolimus increases progression-free survival for women with metastatic breast cancer
New test predicts risk for recurrence for patients with DCIS

The editors and staff of Cure Magazine have been covering the conference by highlighting news through daily written and video blogs. They will be sending out a comprehensive email detailing all their stories on December 15. In order to learn more about the findings presented at the San Antonio Breast Cancer Symposium, sign-up here to receive this email from Cure Magazine.

Sincerely,
The BCT Team